Exchange: NASDAQ·Updated 07:58 PM EST

NRXP News

News
all
press releases
NRx Pharmaceuticals (NASDAQ:NRXP) Stock Dropped to Strong Sell by Wall Street Zen
Wall Street Zen downgraded NRx Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Saturday...
MarketBeat
NRx Pharmaceuticals (NASDAQ:NRXP) Stock Dropped to Strong Sell by Wall Street Zen
Wall Street Zen downgraded NRx Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Saturday...
MarketBeat
More News
Zacks Research raised NRx Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Monday...
MarketBeat
NRx Pharmaceuticals (NRXP) delivered earnings and revenue surprises of +82.76% and -14.15%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
MeiraGTx (MGTX) delivered earnings and revenue surprises of -15.22% and -29.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
NRx Pharmaceuticals shares jump 26.69% after hours as investors await details of a regulatory milestone for its ketamine program.read more...
Benzinga
Shionogi & Co. (SGIOY) delivered earnings and revenue surprises of -38.46% and +5.14%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Ono Pharmaceutical Co. (OPHLF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
NRX Pharmaceuticals (NASDAQ:NRXP) released second-quarter financial results and hosted an earnings call on Monday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensiveread more...
Benzinga
NRx Pharmaceuticals (NRXP) delivered earnings and revenue surprises of -100.00% and -54.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
NRx Pharmaceuticals (NASDAQ:NRXP) reached a potentially significant regulatory milestone after announcing that the U.S. Food and Drug Administration completed its first-cycle review of the company's Abbreviated New Drug Application (ANDA) for preservative-free intravenous ketamine without identifying any major deficiencies related to the drug itself. Instead, the remaining review item involves certification of the product's luer lock vial packaging, a manufacturing documentation issue rather than concerns involving safety, efficacy, labeling, chemistry, manufacturing controls, or the ketamine formulation.
24-7 Market News

Advertisement|Remove ads.